Changes in Beneficial Ownership · 4
Cytokinetics, Incorporated
CYTKNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-31
- Issuer
- CYTOKINETICS INC
- Issuer CIK
- 0001061983
- Trading symbol
- CYTK
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Callos Andrew
- Reporting owner CIK
- 0001852129
- Relationship
- Officer
- Officer title
- EVP, Chief Commercial Officer
- Address
- 350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-31 | M · Form 4 | 10,000 | A | 23.26 | 68,555 | D |
| Common Stock | 2026-08-31 | S · Form 4 | 10,000 | D | 70.24 | 58,555 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy) | 23.26 | 2026-08-31 | M · Form 4 | 10,000 | D | 0 | 2022-03-31[F1] | 2031-03-31 | Common Stock | 10,000 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.↩ 1
Signature 1
- Signed
- /s/ John O. Faurescu, attorney-in-fact for Mr. Callos
- Date
- 2026-08-31
Company context
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.